Biopharmaceutical company ADMA Biologics Inc. (ADMA) is steadily reinforcing its growth outlook, with reaffirmed multi-year financial targets and operational catalysts that continue to shape its trajectory.
For fiscal years 2025 and 2026, ADMA has reaffirmed its expectations for total revenue to exceed $500 million and $625 million, respectively, with adjusted net income projected to surpass $175 million in 2025 and $245 million in 2026.
Subscribe to continue reading the article.
This article is part of our premium content offering.Subscribe with a RTTNews subscription.
Subscribe NowAlready subscribed? Sign in
For comments and feedback: editorial@rttnews.com